You are here
Clinical Genomics is proud to support Strides for Life and Super Bowel I
Overcoming the stigma associated with colorectal cancer screening; former NFL players lead the way by undertaking colonoscopy and InSure ONE FIT testing in Super Bowel I
BRIDGEWATER, N.J., Aug. 24, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics Inc., the manufacturer of the InSure ONE fecal immunochemical test, is proud to be a co-sponsor of Super Bowel I.
On August 25, 2018, former NFL players from the San Francisco 49’ers and the Oakland Raiders, TV personalities and local community members will participate in Super Bowel I, an event to promote screening for colorectal cancer using guideline recommended screening tests. Participants will form two teams ‘SF 49ers Team Freddie Solomon’ and ‘Oakland Raiders team Ken ‘Snake’ Stabler’, in remembrance of Freddie Solomon and Ken Stabler who were both recent victims of colon cancer. Each participant will choose a test, either colonoscopy or Insure ONE FIT, to perform.
Super Bowel I is sponsored by Strides for Life, a non-profit organization that raises awareness about the prevention and early detection of colon cancer. Through contributions from individuals, corporations, and grants; Strides for Life supports awareness and educational programs as well as providing financial aid for colorectal cancer screening.
“We are proud to partner with Clinical Genomics in www.SuperBowel1.com using their InSure ONE FIT test to help promote colon cancer awareness and early screening options,” states Bridget Mannix, Executive Director of Strides for Life, Colon Cancer Foundation.
Fans and supporters are encouraged to support their favorite team in the Battle of the Bay, by voting for a Super Bowel I team and make a donation to Strides for Life at www.superbowel1.com.
“Clinical Genomics is pleased to have the opportunity to participate in this event and support the important work that Strides for Life does for the community,” says Mark Boyle, President of Clinical Genomics IVD.
The American Cancer Society (ACS) recommends that adults aged 45 years and older with an average risk of colorectal cancer undergo regular screening with either a high-sensitivity stool-based test or a structural (visual) examination, depending on patient preference and test availability.
The InSure ONE FIT detects human hemoglobin from blood in fecal samples to aid in the detection of lower gastrointestinal bleeding. A number of medical conditions may be associated with lower gastrointestinal bleeding, including colorectal cancer, iron deficiency, anemia, diverticulitis, ulcerative colitis, polyps, and adenomas. InSure ONE is easy to use, since it only requires a sample of water from the toilet bowl. Following a single bowel movement, the toilet bowl water is collected after brushing the surface of the stool to release any blood into the surrounding water. There’s no requirement to smear or handle fecal matter.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, InSure® ONE™, a one sample FIT used to detect lower GI bleeding, and COLVERA®, a proprietary liquid biopsy blood test identifying circulating tumor DNA for detection of residual disease and early detection of recurrence in post-treatment patients. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.
Mark Boyle, Clinical Genomics (Media): 908-300-8673 (ext. 300)